KemPharm Company Profile (NASDAQ:KMPH)

About KemPharm (NASDAQ:KMPH)

KemPharm logoKemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KMPH
  • CUSIP: N/A
  • Web:
  • Market Cap: $52.77 million
  • Outstanding Shares: 14,657,000
Average Prices:
  • 50 Day Moving Avg: $3.09
  • 200 Day Moving Avg: $3.79
  • 52 Week Range: $2.45 - $5.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($2.68) per share
  • Price / Book: -1.34
  • EBIDTA: ($33,550,000.00)
  • Return on Assets: -51.98%
  • Debt-to-Equity Ratio: -2.34%
  • Current Ratio: 8.40%
  • Quick Ratio: 8.40%
  • Average Volume: 72,061 shs.
  • Beta: -1.28
  • Short Ratio: 8.87

Frequently Asked Questions for KemPharm (NASDAQ:KMPH)

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How were KemPharm's earnings last quarter?

KemPharm, Inc. (NASDAQ:KMPH) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.19. View KemPharm's Earnings History.

When will KemPharm make its next earnings announcement?

KemPharm is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for KemPharm.

Where is KemPharm's stock going? Where will KemPharm's stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for KemPharm's shares. Their predictions range from $7.00 to $13.00. On average, they anticipate KemPharm's share price to reach $9.00 in the next year. View Analyst Ratings for KemPharm.

What are analysts saying about KemPharm stock?

Here are some recent quotes from research analysts about KemPharm stock:

  • 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 10, 2017, 16:01 ET Date and time of production: August 10, 2017, 16:01 ET Target Price / Valuation Methodology: KemPharm – KMPH Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $7/share for KMPH, assuming a stable timeline for KemPharm’s lead products, KP415, KP201/IR and KP511/ER. Additionally, we assume a KP415 launch in 2020 and KP201/IR and KP511/ER launches in 2021. Our valuation assumes a generic launch against KP201/IR around 2031 and generic launches against KP415 and KP511/ER around 2032. This corresponds with the expiries of composition of matter patents, before any FDA term extensions, for all three products." (8/10/2017)
  • 2. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (7/12/2017)

Who are some of KemPharm's key competitors?

Who are KemPharm's key executives?

KemPharm's management team includes the folowing people:

  • Travis C. Mickle Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Timothy J. Sangiovanni, Principal Accounting Officer, Vice President, Corporate Controller
  • Gordon K. Johnson, Chief Business Officer

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

Who owns KemPharm stock?

KemPharm's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include DELAWARE STREET CAPITAL MASTER FUND, L.P. (10.00%), Arete Wealth Advisors LLC (5.81%), Creative Planning (3.10%), C WorldWide Group Holding A S (2.61%), Vanguard Group Inc. (1.70%) and Federated Investors Inc. PA (1.09%). Company insiders that own KemPharm stock include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Institutional Ownership Trends for KemPharm.

Who sold KemPharm stock? Who is selling KemPharm stock?

KemPharm's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Menta Capital LLC, Victory Capital Management Inc. and Creative Planning. View Insider Buying and Selling for KemPharm.

Who bought KemPharm stock? Who is buying KemPharm stock?

KemPharm's stock was bought by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S and Arete Wealth Advisors LLC. Company insiders that have bought KemPharm stock in the last two years include Daniel L Cohen, David S Tierney, Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton and Travis C Mickle. View Insider Buying and Selling for KemPharm.

How do I buy KemPharm stock?

Shares of KemPharm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is KemPharm's stock price today?

One share of KemPharm stock can currently be purchased for approximately $3.60.

MarketBeat Community Rating for KemPharm (NASDAQ KMPH)
Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  223
MarketBeat's community ratings are surveys of what our community members think about KemPharm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for KemPharm (NASDAQ:KMPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.00 (150.00% upside)

Analysts' Ratings History for KemPharm (NASDAQ:KMPH)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/11/2017Canaccord GenuityReiterated RatingBuy$7.00HighView Rating Details
8/10/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$13.00MediumView Rating Details
6/28/2017Roth CapitalInitiated CoverageBuy -> Buy$8.00HighView Rating Details
5/15/2017Royal Bank Of CanadaReiterated RatingBuy$8.00MediumView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for KemPharm (NASDAQ:KMPH)
Earnings by Quarter for KemPharm (NASDAQ:KMPH)
Earnings History by Quarter for KemPharm (NASDAQ KMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.67)N/AView Earnings Details
8/10/2017Q2 2017($0.63)($0.44)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.63)($0.84)ViewN/AView Earnings Details
3/9/2017Q4 2016($0.70)($0.68)ViewListenView Earnings Details
11/9/2016Q3 2016($0.70)($0.92)ViewListenView Earnings Details
8/10/2016Q2($0.94)($0.58)ViewListenView Earnings Details
5/12/2016Q1($0.56)($0.20)ViewListenView Earnings Details
3/10/2016Q4($0.50)($0.64)ViewListenView Earnings Details
11/12/2015Q315($0.48)($0.68)ViewListenView Earnings Details
8/13/2015Q215($0.47)($0.59)ViewListenView Earnings Details
5/27/2015Q1($0.49)($2.50)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for KemPharm (NASDAQ:KMPH)
2017 EPS Consensus Estimate: ($2.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.69)($0.69)($0.69)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.66)($0.66)($0.66)
Q4 20171($0.80)($0.80)($0.80)
(Data provided by Zacks Investment Research)


Dividend History for KemPharm (NASDAQ:KMPH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for KemPharm (NASDAQ:KMPH)
Insider Ownership Percentage: 22.80%
Institutional Ownership Percentage: 40.01%
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Institutional Ownership by Quarter for KemPharm (NASDAQ:KMPH)
Insider Trades by Quarter for KemPharm (NASDAQ:KMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Delaware Street Capital MasterMajor ShareholderBuy325,888$3.27$1,065,653.76View SEC Filing  
8/24/2017Daniel L CohenEVPBuy5,000$2.58$12,900.00View SEC Filing  
8/24/2017Gordon K JohnsonInsiderBuy4,000$2.60$10,400.00View SEC Filing  
6/20/2017Travis C MickleCEOBuy8,000$3.45$27,600.00View SEC Filing  
6/19/2017R. Laduane CliftonCFOBuy275$3.30$907.50View SEC Filing  
5/25/2017Daniel L CohenEVPBuy2,500$4.11$10,275.00View SEC Filing  
3/31/2017Daniel L CohenEVPBuy2,500$4.48$11,200.00View SEC Filing  
3/24/2017R. Laduane CliftonCFOBuy1,000$4.24$4,240.00View SEC Filing  
3/22/2017Travis C MickleCEOBuy2,000$4.10$8,200.00View SEC Filing  
3/20/2017David S TierneyDirectorBuy1,000$4.20$4,200.00View SEC Filing  
11/30/2016Daniel L CohenEVPBuy5,000$3.50$17,500.00View SEC Filing  
9/6/2016Daniel L CohenEVPBuy10,000$4.75$47,500.00View SEC Filing  
8/17/2016Travis C MickleCEOBuy5,000$4.95$24,750.00View SEC Filing  
3/29/2016Travis C MickleCEOBuy2,450$14.57$35,696.50View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for KemPharm (NASDAQ:KMPH)
Latest Headlines for KemPharm (NASDAQ:KMPH)
DateHeadline logoKemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate - September 21 at 12:29 PM logoKemPharm, Inc. (KMPH) Earns Buy Rating from Canaccord Genuity - September 17 at 10:22 PM logoKemPharm, Inc. (KMPH) Given Average Rating of "Buy" by Brokerages - September 16 at 3:10 AM logoKemPharm, Inc. (KMPH) Major Shareholder Delaware Street Capital Master Acquires 325,888 Shares - September 15 at 4:30 PM logoAstellas, KMPH, SRNE To Face FDA, ALXN Trims Workforce, ALDX Soars On Trial Data - September 13 at 3:33 AM logoKemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA - September 13 at 3:33 AM logoKemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - September 1 at 1:55 AM logoKemPharm, Inc. (KMPH) Insider Buys $10,400.00 in Stock - August 25 at 8:54 PM logoKemPharm, Inc. (KMPH) EVP Daniel L. Cohen Buys 5,000 Shares - August 25 at 8:54 PM logoKemPharm, Inc. (KMPH) Given Consensus Rating of "Buy" by Brokerages - August 22 at 2:58 AM logoKemPharm, Inc. (KMPH) Expected to Announce Earnings of -$0.69 Per Share - August 21 at 6:14 AM logoKemPharm, Inc. (KMPH) Given a $13.00 Price Target at Oppenheimer Holdings, Inc. - August 13 at 6:32 PM logoKemPharm (KMPH) Announces Prelim. Results from KP415 Pharmacokinetic Single and Multiple Dose Trial - August 12 at 1:54 AM logoKemPharma reports 2Q loss - August 12 at 1:54 AM logoKemPharm, Inc. (NASDAQ:KMPH) Issues Quarterly Earnings Results - August 11 at 5:16 PM logoKemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial - August 11 at 5:49 AM logoKemPharm, Inc. Reports Second Quarter 2017 Results - August 11 at 5:49 AM logoKemPharm's (NASDAQ:KMPH) "Buy" Rating Reaffirmed at Canaccord Genuity - August 10 at 6:26 PM logoKemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety - August 8 at 7:59 PM logoKemPharm to Present at Canaccord Genuity 37th Annual Growth Conference - August 3 at 11:31 PM logoZacks: Analysts Expect KemPharm, Inc. (KMPH) Will Post Earnings of -$0.63 Per Share - August 3 at 7:26 AM logoKemPharm, Inc. to Report Second Quarter 2017 Results - August 2 at 2:46 AM logoKemPharm, Inc. (NASDAQ:KMPH) Receives Average Rating of "Buy" from Brokerages - July 28 at 11:21 AM logoZacks: Brokerages Expect KemPharm, Inc. (KMPH) Will Announce Earnings of -$0.63 Per Share - July 11 at 6:14 PM logoKemPharm, Inc. (KMPH) Lowered to "Strong Sell" at ValuEngine - July 8 at 10:10 PM logoKemPharm, Inc. (KMPH) Receives Consensus Recommendation of "Hold" from Brokerages - July 3 at 12:04 PM logoKemPharm, Inc. (KMPH) Now Covered by Roth Capital - July 2 at 3:08 PM logoKemPharm, Inc. (KMPH) Lifted to "Sell" at ValuEngine - July 1 at 8:08 PM logoKemPharm (KMPH) Announced Two Advances Involving its Prodrug Development Pipeline to Treat ADHD - June 30 at 12:52 AM logoKemPharm (KMPH) Strengthens its ADHD Prodrug Pipeline - June 30 at 12:51 AM logoKemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate - June 28 at 7:45 PM logoKemPharm (KMPH) Granted First Patent for KP746 - June 26 at 8:05 PM logoKemPharm Announces First Patent Grant for KP746, a Prodrug of Oxymorphone - June 26 at 8:05 PM logoKemPharm, Inc. (KMPH) CEO Buys $27,600.00 in Stock - June 21 at 1:25 PM logoKemPharm, Inc. (KMPH) Expected to Post Earnings of -$0.63 Per Share - June 15 at 6:28 PM logoKemPharm to Present Clinical Data for KP511, an Opioid Prodrug Candidate, at the International Conference on Opioids - June 9 at 9:20 AM logoKemPharm Announces Addition to Leadership Team - June 1 at 7:51 AM logoKemPharm Inc (KMPH) Lowered to "Sell" at Zacks Investment Research - May 28 at 5:56 PM logoDaniel L. Cohen Purchases 2,500 Shares of KemPharm Inc (KMPH) Stock - May 26 at 8:29 PM logoQ2 2017 EPS Estimates for KemPharm Inc Reduced by Oppenheimer Holdings (KMPH) - May 15 at 7:46 AM logoFY2021 EPS Estimates for KemPharm Inc (KMPH) Cut by Analyst - May 12 at 6:56 PM logoKemPharm Inc (KMPH) Announces Quarterly Earnings Results - May 11 at 7:36 PM logoKemPharm Inc (KMPH) Given a $13.00 Price Target by Oppenheimer Holdings Inc. Analysts - May 11 at 2:56 PM logoKemPharma reports 1Q loss - May 10 at 6:06 PM logoKemPharm, Inc. Reports First Quarter 2017 Results - May 10 at 6:06 PM logoInvestor Network: KemPharm, Inc. to Host Earnings Call - May 10 at 1:04 PM logoKemPharm Inc (KMPH) Rating Increased to Buy at Zacks Investment Research - May 5 at 12:46 AM logoKemPharm (KMPH) Receiving Somewhat Favorable Press Coverage, Report Finds - May 4 at 2:18 PM logoKemPharm Inc (KMPH) Downgraded by Zacks Investment Research - May 4 at 1:17 AM logoZacks Investment Research Downgrades KemPharm Inc (KMPH) to Hold - May 4 at 1:16 AM



KemPharm (KMPH) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff